Join us for a deep dive into #EngineeringBiology—where biology meets technology to solve #GlobalChallenges 🌱Hear from top speakers on cutting-edge breakthroughs in #SynBio, #Biotech, and more ➡ ow.ly/Iqh450TnRGs 📌 Rebecca Godfrey PhD, COO, ExpressionEdits 📌 James

Campus-based ExpressionEdits features in this Labiotech.eu compilation of 10 start-ups to watch in 2024. They are deemed 'likely to make a big splash in the biotech sector'. Congrats team! ow.ly/TPMT50TBi6k

Here to present the company showcase winners is Bianca De Blasi, PhD, Senior Data Scientist, Citeline . #Congratulations 🎉 to all our final innovative showcase winners in #EngineeringBiology, #Genomics, and #AI & data ⬇️ ✨ Rebecca Godfrey PhD, COO, ExpressionEdits ✨

🌟 What an extraordinary day we had yesterday at #TechBioUK 2024! We want to take this moment to thank everyone who joined us 🎉 Your engagement, passion, and expertise created an inspiring atmosphere that showcased the very best of our industry 👏 A special thank you to our

Campus-based BenevolentAI and ExpressionEdits feature in the BioIndustry Association (BIA) '#TechBio: UK leads innovation frontier' report as two of the companies driving UK innovation. There's also a case study on Accelerate@Babraham alumni Enhanc3DGenomics. Explore - techbio.org.uk

🧵 Europe’s rising biotech stars: 10 startups to watch in 2024: Quotient Therapeutics Bioptimus Relation ExpressionEdits, Draupnir Bio, Infinitopes, Adcytherix, Commit Biologics, Artica Therapeutics, Cumulus Oncology | Roohi Mariam Peter Labiotech.eu labiotech.eu/best-biotech/e…

Super excited to welcome Wave Life Sciences CEO Paul Bolno to ExpressionEdits board 🎇 businessweekly.co.uk/posts/dr-paul-…

More coverage on Paul Bolno appointment: biopharmatrend.com/post/1083-expr…

The 2024 UK biotech financing report from the BioIndustry Association (BIA) is out highlighting the sector's innovation and global appeal. Campus-based ExpressionEdits and Shift Bioscience both feature in the ranking of top seed deals. 🙌 Explore 👉 ow.ly/Ngu350UPRgT #InvestinBiotech

Some great new out of ExpressionEdits today! Can't wait to see what our introns can do in gene therapy!

Hello Genetic Syntax Engine! "ExpressionEdits is essentially reintroducing punctuation into the genome’s language, creating clearer and more accurate instructions for protein production" thereby accelerating the development of gene therapies. Big news indeed for

ExpressionEdits in a partnership that will focus on using its AI-based platform to design introns that improve protein expression for novel gene therapies that are being developed by Boehringer Ingelheim for some undisclosed targets. hubs.li/Q036npGk0

Boehringer Ingelheim taps ExpressionEdits' AI to develop gene therapies Boehringer Ingelheim ExpressionEdits #AI #genetherapy firstwordhealthtech.com/story/5934718

Campus-based ExpressionEdits has shared details of a collaboration and licensing agreement with Boehringer Ingelheim to bring first-in-class gene therapies to patients. Full story 👉ow.ly/sTAe50UYFuZ

When with Kärt Tomberg we incorporated ExpressionEdits in 2021 I remember we published some of the early findings on X and were flooded with expressions of interests by fellow researchers and biotech entrepreneurs to collaborate, which was great: the truest form (especially in

Check out this article from Cambridge Independent covering Campus-based ExpressionEdits' collaboration and licensing agreement with Boehringer Ingelheim ow.ly/6g0R50V6QO7

Campus-based ExpressionEdits has appointed Dr Amrik Basran as Chief Scientific Officer to lead the translation of its intronization technology into a pipeline of innovative therapeutics, starting with recombinant protein therapeutics. Full story 👇 ow.ly/OXGx50VjSaC

🚀 Join us on 22nd May for the return of Start-up Festival ➡️ ow.ly/p7bR50VxZlf Our expert panel will dive into what’s working for start-ups in 2025, including trends, challenges, and real-world wins. 💡 🔺 Rebecca Godfrey PhD, COO, ExpressionEdits 🔺 Özgür Tuncer, CEO &